COMMUNIQUÉS West-GlobeNewswire

Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701
14/05/2025
Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance mutations Early dose-escalation data from Phase 1 CARDINAL study [...]
Autonomix CEO Brad Hauser to Present at Virtual Investor’s Closing Bell Event
14/05/2025
Live webcast followed by an interactive Q&A session on Thursday, May 22 nd at 4:00 PM ET Access the event here THE WOODLANDS, TX, May 14, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” [...]
Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform
14/05/2025
New Proprietary Target Discovery and Validation Platform Integrates Multiomics, Contingent AI, Phenoclustering, and CRISPR Screens to Accelerate Drug Discovery LOS ANGELES, May 14, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc [...]
Vivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference Call
14/05/2025
Call Scheduled for Thursday, May 15, 2025 at 5:00 pm ET LITTLETON, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS) , a leading medical device and technology [...]
Progyny Appoints Two Renowned Women’s Health Experts to Medical Advisory Board
14/05/2025
Medical Advisory Board additions support company’s growing product offerings across women’s health and family building NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s [...]
Outset Medical Appoints Industry Veteran Kevin O’Boyle to its Board of Directors
14/05/2025
SAN JOSE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, [...]
Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD
14/05/2025
– Expect to report topline data from the Seabreeze STAT COPD study in 1H 2026 – SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), [...]
The Dwayne Andrews Glioblastoma Research Grant Awarded to Dr. Jeremy Brown, Dalhousie University
14/05/2025
TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Brain Cancer Canada is proud to announce The Dwayne Andrews Glioblastoma Research Grant of $85,000 awarded to Dr. Jeremy Brown at Dalhousie University for his project, "Clinical [...]
Epilepsy Foundation of America to Present Lifetime Accelerator Award to Orrin Devinsky, M.D.
14/05/2025
Renowned Neurologist and Epilepsy Advocate Honored for Decades of Innovation in Therapeutics, Research, and Patient Care BOWIE, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Internationally acclaimed neurologist and epilepsy [...]
Cannabix Enters Sales Distribution Agreement with Australian Distributor for BreathLogix Autonomous Alcohol Breathalyzer
14/05/2025
Cannabix has developed an autonomous alcohol breathalyzer screening device for employers and a range of industries and safety settings VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies [...]
Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results
14/05/2025
- VCN-01 Achieves Primary Efficacy and Safety Endpoints for Pancreatic Ductal Adenocarcinoma in VIRAGE Phase 2b Clinical Trial - - Closed a public offering on May 8, 2025, raising the Company’s cash balance and [...]
Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories
14/05/2025
Clear Regulatory Path to Clinical Trials for Intranasal PTSD Therapy Targeting Multi-Billion-Dollar Market SARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a [...]
Neuronetics Launches First Inaugural National TMS Therapy Awareness Day During Mental Health Awareness Month
14/05/2025
New national awareness day will foster greater understanding of transcranial magnetic stimulation (TMS) treatment The company will celebrate on social media, sharing patient and provider stories that highlight the [...]
Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway
14/05/2025
Newly granted patent is part of the expanding intellectual property portfolio directed to: -generating novel and selective Wnt surrogate molecules with potentially broad therapeutic utility and -incorporating novel [...]
Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations
14/05/2025
New entity, ErnexaTX2, reflects progress toward clinical readiness CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of [...]
UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder
14/05/2025
- ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available in the U.S. - - Ann & Robert H. Lurie Children's Hospital of [...]
IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights
14/05/2025
Primary endpoint of pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine in patients with advanced melanoma still expected to readout in third quarter of 2025 Data presented at [...]
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
14/05/2025
BRISBANE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, [...]
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update
14/05/2025
ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial Three patients in the 550 [...]

Pages